Affiliation:
1. Department for Pediatric Pneumology, Allergology and Neonatology,
Hannover Medical School, Hannover, Germany
Abstract
AbstractPulmonary alveolar proteinosis (PAP) is an umbrella term used to refer to a
pulmonary syndrome which is characterized by excessive accumulation of
surfactant in the lungs of affected individuals. In general, PAP is a rare lung
disease affecting children and adults, although its prevalence and incidence is
variable among different countries. Even though PAP is a rare disease, it is a
prime example on how modern medicine can lead to new therapeutic concepts,
changing ways and techniques of (genetic) diagnosis which ultimately led into
personalized treatments, all dedicated to improve the function of the impaired
lung and thus life expectancy and quality of life in PAP patients. In fact, new
technologies, such as new sequencing technologies, gene therapy approaches, new
kind and sources of stem cells and completely new insights into the ontogeny of
immune cells such as macrophages have increased our understanding in the onset
and progression of PAP, which have paved the way for novel therapeutic concepts
for PAP and beyond. As of today, classical monocyte-derived macrophages are
known as important immune mediator and immune sentinels within the innate
immunity. Furthermore, macrophages (known as tissue resident macrophages (TRMs))
can also be found in various tissues, introducing e. g. alveolar
macrophages in the broncho-alveolar space as crucial cellular determinants in
the onset of PAP and other lung disorders. Given recent insights into the onset
of alveolar macrophages and knowledge about factors which impede their function,
has led to the development of new therapies, which are applied in the context of
PAP, with promising implications also for other diseases in which macrophages
play an important role. Thus, we here summarize the latest insights into the
various forms of PAP and introduce new pre-clinical work which is currently
conducted in the framework of PAP, introducing new therapies for children and
adults who still suffer from this severe, potentially life-threatening
disease.
Reference69 articles.
1. “Pulmonary Alveolar Proteinosis Syndrome,”;A Kelly;Semin Respir Crit Care Med,2020
2. “The role of lipids in pulmonary surfactant,”;R Veldhuizen;Biochim. Biophys. Acta - Mol. Basis Dis.,1998
3. “Surfactant granulocyte rnetabolism in transgenic mice after stimulating
factor ablation,”;M Ikegami;Am J Physiol,1996
4. “Distinct changes in pulmonary surfactant homeostasis in common
β-chain- and GM-CSF-deficient mice,”;J A Reed;Am. J. Physiol. - Lung Cell. Mol. Physiol.,2000
5. “Characteristics of a large cohort of patients with autoimmune pulmonary
alveolar proteinosis in Japan,”;Y Inoue;Am. J. Respir. Crit. Care Med.,2008
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献